Ffernandes_MD

Clinical Pathologist 🇪🇺🇵🇹MD, MSc// Physician-scientist aspirant// Halb Deutscher 🇩🇪

[Vincent Rajkumar @VincentRK]

The serum free light chain FLC assay. Tutorial. #MedTwitter #MyelomaVR

Frequently ordered and frequently abnormal. This thread will reduce unnecessary headaches and referrals.

1/ Don’t order it unless you are suspecting myeloma, amyloid or related disorder

[Benlazar S M A @smbenlazar]

Diagnosis of enteropathy-associated T-cell lymphoma (EATL) on peripheral blood: A pleiomorphic morphology and an unusual immunophenotype https://t.co/2vTta4TIDj #lymsm

[Mirco J. Friedrich @mircoscopy]

My first cover story in this month's issue of @Cancer_Cell! 🍾

"On the cover: Friedrich et al. (711–725) reveal the mode of action of bispecific antibodies in patients with multiple myeloma."

Check it out:
https://t.co/kA5G16XLYN
https://t.co/MNgCa8SaVA

[Ffernandes_MD @FfernandesMd]

@WilliamAird4 @jlberrymd @MatthewChaseMD @Scopio_Labs Sign up not working also

[Journal of Clinical Oncology @JCO_ASCO]

🧐 A new open-access tool identifies #MultipleMyeloma and light-chain #Amyloidosis demonstrating MGUS-like phenotype with distinct clinical outcomes ��️ https://t.co/FlthW4ZcQ2 #JCO #MMSM @BrunoPaiva_UNAV

[William Aird @WilliamAird4]

1/3

FOCUS ON MCHC, NOT MCH

When choosing between mean corpuscular Hb (MCH; weight of RBC in Hb) and mean MCHC (the concentration of Hb inside the cell; think central pallor), it is the latter that provides discriminatory power in the ddx of anemia.

[William Aird @WilliamAird4]

AN APPROACH TO MACROCYTOSIS

[Ffernandes_MD @FfernandesMd]

Here we go again to Bissau 🤓🥰 https://t.co/WfgTAI2oCI

[William Aird @WilliamAird4]

4/4

Why us the term iron deficiency anemia (IDA) to describe a patient whose main complaint is pica or restless legs? Why not refer to IDA as iron deficiency WITH anemia (to separate it from non-anemic ID and acknowledge other manifestations of ID)?

Just thinking out loud 😀

[Buku Haematology 🅰️➕ @BukuHaematology]

Coagulation studies can sometimes be hard to interpret, so here are a few tips 👇

[Ilya Shabanov @Artifexx]

Here is my method to conduct (and automate) a literature review.

Using Google Scholar, @scite , @litmaps , #ChatGPT, @zotero and @obsdmd.

Tutorial with examples and best practices:
👇

[Konstantinos I. Bougioukas @Bugiukas]

The online textbook "Practical Statistics in Medicine with R" is based on my notes from a series of practical labs at University and it is completely free for everyone.
https://t.co/8Cr7Dptffj

#rstats #QuartoPub #AwesomeQuarto #tidyverse #dataviz #statistics #datascience

[Fernando Martín Moro @Fer_martinmoro]

All we see is VEXAS? 🤔🔬 #PathTwitter #cytopath

[Munich Leukemia Laboratory @leukaemielabor]

📄Based on #karyotype and #mutation status of 9 genes -25 genes in a subset of cases- #MDS can be separated into 9 biologically distinct subgroups. The groups better reflect biology than blast counts & might also help to refine therapeutic strategies.
https://t.co/je5QucFEHK

[Uriel Suárez @UsuarezMD]

T-lymphocytic variant of HES.

REMEMBER:

• elevated serum immunoglobulin E (IgE)
• skin involvement, and
• lymphadenopathy.

[Vincent Alcazer @AlcazerVincent]

How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
https://t.co/PvRKYB9H0u

[Menendez Lab @Menendez_Lab]

Que grande @LabOrfao ! Habría que explicarles a nuestros políticos lo que este investigador es capaz de contribuir a la internacionalización de España en diagnóstico, clínica, educación e generación de empleo productivo y propiedad intelectual por cada Euro que le financiamos !

[Ffernandes_MD @FfernandesMd]

ASH 2022 discussions. Merry Christmas 🎄🎁 https://t.co/5MQRnewyUU

[Vincent Rajkumar @VincentRK]

In 2022 we had two more new treatments approved for myeloma: cilta-cel (CAR-T therapy) and teclistamab (BCMA bispecific).

We are making steady progress. #MedTwitter

[Brooj Abro, MD @BroojAbro]

Peripheral blood 🩸

What are these cells…
@Pyromutate @alnoorakber #hemepath